These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 24201746)

  • 21. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M; Sohda M; Miyazaki T; Honjo H; Hara K; Ozawa D; Suzuki S; Tanaka N; Yokobori T; Kuwano H
    Hepatogastroenterology; 2015 Jun; 62(140):898-901. PubMed ID: 26902024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY; Kim SK; Nam BH; Min SY; Lee SJ; Park C; Kwon Y; Kim EA; Ko KL; Park IH; Lee KS; Shin KH; Lee S; Kim SW; Kang HS; Ro J
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of metabolic response measured by 18F-FDG-PET in oesophageal cancer patients treated with definitive chemoradiotherapy.
    Onal C; Torun N; Guler OC; Yildirim BA
    Nucl Med Commun; 2016 Dec; 37(12):1282-1289. PubMed ID: 27612030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma.
    Makino T; Miyata H; Yamasaki M; Fujiwara Y; Takiguchi S; Nakajima K; Higuchi I; Hatazawa J; Mori M; Doki Y
    Surgery; 2010 Nov; 148(5):908-18. PubMed ID: 20378140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma.
    Swisher SG; Erasmus J; Maish M; Correa AM; Macapinlac H; Ajani JA; Cox JD; Komaki RR; Hong D; Lee HK; Putnam JB; Rice DC; Smythe WR; Thai L; Vaporciyan AA; Walsh GL; Wu TT; Roth JA
    Cancer; 2004 Oct; 101(8):1776-85. PubMed ID: 15386332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
    Groheux D; Biard L; Giacchetti S; Teixeira L; Hindié E; Cuvier C; Vercellino L; Merlet P; de Roquancourt A; de Cremoux P; Resche-Rigon M; Espié M
    J Nucl Med; 2016 Apr; 57(4):536-43. PubMed ID: 26697967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy.
    Myslivecek M; Neoral C; Vrba R; Vomackova K; Cincibuch J; Formanek R; Koranda P; Zapletalova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2012 Jun; 156(2):171-9. PubMed ID: 22660205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results.
    Mamede M; Abreu-E-Lima P; Oliva MR; Nosé V; Mamon H; Gerbaudo VH
    Am J Clin Oncol; 2007 Aug; 30(4):377-88. PubMed ID: 17762438
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Utility and drawbacks of fludeoxyglucose-positron emission tomography in locally advanced esophageal cancer treated by neoadjuvant chemotherapy followed by esophagectomy].
    Takemura M; Yamashita H; Kaibe N; Takii M; Niwa H; Oshima T; Kikuchi S; Sasako M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):2143-5. PubMed ID: 24394040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of 18F-FDG-PET-CT for Assessment of Response to Neoadjuvant Chemotherapy in Children With Wilms Tumor.
    Qin Z; Tang Y; Wang H; Cai W; Fu H; Li J; Ma C
    J Pediatr Hematol Oncol; 2015 Jul; 37(5):396-401. PubMed ID: 25749587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PET/CT predicts survival in patients undergoing primary surgery for esophageal cancer.
    Lindner K; Palmes D; Senninger N; Hummel R
    Langenbecks Arch Surg; 2015 Feb; 400(2):229-35. PubMed ID: 25572665
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Prognostic Impact of Early Change in 18F-FDG PET SUV After Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer.
    Lee HW; Lee HM; Choi SE; Yoo H; Ahn SG; Lee MK; Jeong J; Jung WH
    J Nucl Med; 2016 Aug; 57(8):1183-8. PubMed ID: 27033896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
    Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
    Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.
    Port JL; Lee PC; Korst RJ; Liss Y; Meherally D; Christos P; Mazumdar M; Altorki NK
    Ann Thorac Surg; 2007 Aug; 84(2):393-400; discussion 400. PubMed ID: 17643605
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography.
    Brücher BL; Weber W; Bauer M; Fink U; Avril N; Stein HJ; Werner M; Zimmerman F; Siewert JR; Schwaiger M
    Ann Surg; 2001 Mar; 233(3):300-9. PubMed ID: 11224616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor Response in Esophageal Squamous Cell Carcinoma Treated With Neoadjuvant Chemotherapy Followed by Surgery.
    Ohsawa M; Hamai Y; Emi M; Takaoki F; Ibuki Y; Tomoaki K; Yoshikawa T; Okada M
    Anticancer Res; 2020 Feb; 40(2):1153-1160. PubMed ID: 32014968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definitive chemo-radiotherapy for squamous cell carcinoma of the pharynx: impact of baseline low hemoglobin level (<12 g/dL) and post-radiation therapy F-18 FDG-PET/CT.
    Katahira-Suzuki R; Hata M; Tateishi U; Taguchi T; Takano S; Omura-Minamisawa M; Inoue T
    Ann Nucl Med; 2015 Jan; 29(1):37-45. PubMed ID: 25228378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of
    Wang X; Yang W; Zhou Q; Luo H; Chen W; Yeung SJ; Zhang S; Gan Y; Zeng B; Liu Z; Feng S; Zhang X; Cheng C
    Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4241-4251. PubMed ID: 35732974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.